Pharma BD Deal Intelligence
A $2B option-based collaboration that Celgene later converted into full ownership by acquiring Juno outright for $9B in 2018. The deal delivered Breyanzi (lisocabtagene maraleucel) for B-cell lymphoma, CLL, and ALL, though Celgene itself was acquired by BMS just a year later.
Celgene and Juno announce 10-year collaboration for CAR-T immunotherapies with $1B total investment.
Celgene to pay $1 billion for decade-long partnership with Juno Therapeutics to develop immunotherapies for cancer and autoimmune diseases.
Source summaries from our enrichment pipeline; follow links for originals.
All 3 sources with sentiment breakdown →
Celgene and Juno Therapeutics entered a global collaboration for CAR-T and TCR cell therapies. Celgene paid $150M upfront plus $850M in equity investment, with up to $1B in milestones. Celgene gained options to co-develop/co-commercialize candidates including liso-cel (Breyanzi). Celgene subsequently acquired Juno for $9B in January 2018, and BMS acquired Celgene in 2019 inheriting all programs.
72K US cases/yr · $3.0B Projected CAR-T Market (2020) · ~50% DLBCL CR Rate (liso-cel)
CAR-T cell therapy engineers a patient's T cells to destroy cancer. Juno's liso-cel (Breyanzi) used a defined CD4/CD8 composition for improved consistency vs. first-gen CAR-T products.
Celgene acquired Juno for $9B in 2018. BMS inherited via 2019 Celgene acquisition. Breyanzi approved 2021 for large B-cell lymphoma, expanded to 2L. $571M revenue in 2023.
Celgene paid $150M upfront + $850M equity for CAR-T/TCR cell therapy development. Up to $1B milestones.
FDA approved Breyanzi for r/r LBCL. 73% ORR, 54% CR in TRANSCEND NHL 001. Celgene/BMS deal validated.
Breyanzi has 5 FDA approvals (most of any CD19 CAR-T). Expanded to FL, MCL, CLL/SLL, MZL. Juno acquired by Celgene for $9B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Bristol-Myers Squibb Company (this deal) | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
| Celgene Corporation / Gloucester Pharmaceuticals, Inc. | 2009 | $640M | 40 |
← Browse all deals · How we score deals
More: 2015 deals · Celgene Corporation deals · Gene Therapy deals